Union Diagnostic and Clinical Services Plc provides laboratory and clinical services primarily in Nigeria.
Price History & Performance
|Historical stock prices|
|Current Share Price||₦0.28|
|52 Week High||₦0|
|52 Week Low||₦0|
|1 Month Change||0%|
|3 Month Change||0%|
|1 Year Change||7.69%|
|3 Year Change||0%|
|5 Year Change||-44.00%|
|Change since IPO||-89.82%|
Recent News & Updates
|UNIONDAC||NG Healthcare||NG Market|
Return vs Industry: UNIONDAC underperformed the NG Healthcare industry which returned 28.9% over the past year.
Return vs Market: UNIONDAC underperformed the NG Market which returned 40% over the past year.
Stable Share Price: UNIONDAC is less volatile than 75% of NG stocks over the past 3 months, typically moving +/- 0% a week.
Volatility Over Time: UNIONDAC's weekly volatility has decreased from 5% to 0% over the past year.
About the Company
Union Diagnostic and Clinical Services Plc provides laboratory and clinical services primarily in Nigeria. The company offers pathology services in the areas of chemical pathology, immunoassay, haematology and blood transfusion, microbiology, parasitology, virology, molecular lab and DNA testing, mycology, and cytology and histology; ultrasound, X-ray imaging, mammography, CT scan, and MRI services; and ECG, EEG, audiometry, and spirometry services. It also provides gastroscopy, colonoscopy, sigmoidoscopy proctoscopy, laparoscopy and dye test, bronchoscopy, and cystoscopy services, as well as renal dialysis services.
Union Diagnostic and Clinical Services Fundamentals Summary
|UNIONDAC fundamental statistics|
Is UNIONDAC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|UNIONDAC income statement (TTM)|
|Cost of Revenue||₦425.64m|
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
|Earnings per share (EPS)||0.0058|
|Net Profit Margin||1.45%|
How did UNIONDAC perform over the long term?See historical performance and comparison
Is Union Diagnostic and Clinical Services undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate UNIONDAC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate UNIONDAC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: UNIONDAC is poor value based on its PE Ratio (48.2x) compared to the African Healthcare industry average (32.3x).
PE vs Market: UNIONDAC is poor value based on its PE Ratio (48.2x) compared to the NG market (7.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate UNIONDAC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: UNIONDAC is good value based on its PB Ratio (0.2x) compared to the XF Healthcare industry average (2.7x).
How is Union Diagnostic and Clinical Services forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Union Diagnostic and Clinical Services has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Union Diagnostic and Clinical Services performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UNIONDAC has a high level of non-cash earnings.
Growing Profit Margin: UNIONDAC's current net profit margins (1.5%) are lower than last year (4.6%).
Past Earnings Growth Analysis
Earnings Trend: UNIONDAC's earnings have declined by 44.3% per year over the past 5 years.
Accelerating Growth: UNIONDAC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: UNIONDAC had negative earnings growth (-66.6%) over the past year, making it difficult to compare to the Healthcare industry average (4.5%).
Return on Equity
High ROE: UNIONDAC's Return on Equity (0.5%) is considered low.
How is Union Diagnostic and Clinical Services's financial position?
Financial Position Analysis
Short Term Liabilities: UNIONDAC's short term assets (NGN2.4B) exceed its short term liabilities (NGN159.9M).
Long Term Liabilities: UNIONDAC's short term assets (NGN2.4B) do not cover its long term liabilities (NGN2.6B).
Debt to Equity History and Analysis
Debt Level: UNIONDAC's debt to equity ratio (58.1%) is considered high.
Reducing Debt: UNIONDAC's debt to equity ratio has increased from 1.2% to 58.1% over the past 5 years.
Debt Coverage: UNIONDAC's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: UNIONDAC earns more interest than it pays, so coverage of interest payments is not a concern.
What is Union Diagnostic and Clinical Services's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate UNIONDAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate UNIONDAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UNIONDAC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UNIONDAC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of UNIONDAC's dividend in 3 years as they are not forecast to pay a notable one for the NG market.
How experienced are the management team and are they aligned to shareholders interests?
Dr. A. Olusola Akinniyi, MB, BS, MBA, FWACS serves as the Managing Director, Chief Executive Officer and a Director at Union Diagnostic and Clinical Services Plc. Mr. Akinniyi is a Consultant Gynaecologist...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Union Diagnostic and Clinical Services Plc's employee growth, exchange listings and data sources
- Name: Union Diagnostic and Clinical Services Plc
- Ticker: UNIONDAC
- Exchange: NGSE
- Founded: 1994
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: ₦994.879m
- Shares outstanding: 3.55b
- Website: https://www.uniondiagnostic.com.ng
Number of Employees
- Union Diagnostic and Clinical Services Plc
- 5, Eletu Ogabi Street
- Off Adeola Odeku Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/17 15:22|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.